Skip to content

Study · In vitro (cells) · 2004

6 results

The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.

Gozes I, Divinski I

Journal of Alzheimer's disease : JAD1 Dec 2004Cited by 62 (Europe PMC)

PMID15665412 (opens in a new tab)DOI10.3233/jad-2004-6s605 (opens in a new tab)PepBankPUB-15665412
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In vitro, NAP promoted microtubule assembly.

    In plain wordsIn lab tests, NAP promoted microtubule assembly.

    Peptide
    Davunetide
    Outcome
    IncreaseMicrotubule assembly
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    10(-15) MAs given in this study.

    Source sentences

    Summary
    NAP (10(-15) M) promoted microtubule assembly in vitro and protected astrocytes against zinc intoxication which is associated with microtubule disruption.
  2. 02LabIn vitro (cells)Efficacy outcome

    In astrocytes, NAP protected against zinc intoxication associated with microtubule disruption.

    In plain wordsIn lab tests, NAP protected astrocytes against zinc toxicity.

    Peptide
    Davunetide
    Outcome
    IncreaseProtection against zinc intoxication
    Study

    n: not reported in source

    Astrocytes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10(-15) MAs given in this study.

    Source sentences

    Summary
    NAP (10(-15) M) promoted microtubule assembly in vitro and protected astrocytes against zinc intoxication which is associated with microtubule disruption.
  3. 03LabIn vitro (cells)Mechanism

    In astrocytes, NAP incubation caused microtubule reorganization.

    In plain wordsIn lab tests, NAP changed the organization of microtubules in astrocytes.

    Peptide
    Davunetide
    Outcome
    Not applicableMicrotubule reorganization
    Study

    n: not reported in source

    Astrocytes
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    femtomolar concentrations · two hoursAs given in this study.

    Source sentences

    Summary
    A two hour incubation period of astrocytes with femtomolar concentrations of NAP resulted in microtubule re-organization and transient increases in immunoreactive non-phosphorylated tau.
  4. 04LabIn vitro (cells)Mechanism

    In astrocytes, NAP incubation transiently increased immunoreactive non-phosphorylated tau.

    In plain wordsIn lab tests, NAP temporarily increased non-phosphorylated tau immunoreactivity in astrocytes.

    Peptide
    Davunetide
    Outcome
    IncreaseNon-phosphorylated tau immunoreactivity
    Study

    n: not reported in source

    Astrocytes
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    femtomolar concentrations · two hoursAs given in this study.

    Source sentences

    Summary
    A two hour incubation period of astrocytes with femtomolar concentrations of NAP resulted in microtubule re-organization and transient increases in immunoreactive non-phosphorylated tau.
  5. 05LabIn vitro (cells)Pharmacokinetics

    In astrocytes, NAP penetrated membranes before tubulin binding and microtubule assembly.

    In plain wordsIn lab tests, NAP entered astrocytes before binding tubulin and promoting microtubule assembly.

    Peptide
    Davunetide
    Outcome
    Not applicableMembrane penetration
    Study

    n: not reported in source

    Astrocytes
    Outcome group
    Pharmacokinetics · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NAP structure allows membrane penetration, followed by tubulin binding and facilitation of microtubule assembly toward cellular protection in astrocytes.
  6. 06LabIn vitro (cells)Mechanism

    In laboratory experiments, tubulin was identified as a NAP binding molecule.

    In plain wordsIn lab tests, researchers identified tubulin as a molecule that binds NAP.

    Peptide
    Davunetide
    Outcome
    Not applicableTubulin binding
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tubulin, the major subunit protein of microtubules, was identified as a NAP binding molecule.
    1 context sentence
    Summary · context
    NAP structure allows membrane penetration, followed by tubulin binding and facilitation of microtubule assembly toward cellular protection in astrocytes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00505765

A Multicenter Study of NAP (AL-108) in Schizophrenia

University of California, Los Angelesn = 63Jul 2007 to Apr 2009

Schizophrenia

Trial pageClinicalTrials.govUpdated 10 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.